IgA nephropathy

被引:2
|
作者
Pillebout, Evangeline [1 ]
Verine, Jerome [2 ]
机构
[1] Hop St Louis, Serv Nephrol, 1 Ave Claude Vellefaux, F-75010 Paris, France
[2] Hop St Louis, Serv Anat Pathol, 1 Ave Claude Vellefaux, F-75010 Paris, France
来源
NEPHROLOGIE & THERAPEUTIQUE | 2016年 / 12卷 / 04期
关键词
Chronic kidney disease; Hematuria; IgA; Nephropathy; Primary glomerulonephritis; Renine-angiotensin-aldosterone blockers; ANGIOTENSIN-CONVERTING-ENZYME; IMMUNOGLOBULIN-A NEPHROPATHY; STEROID PULSE THERAPY; MYCOPHENOLATE-MOFETIL TREATMENT; HENOCH-SCHONLEIN PURPURA; IMMUNE-COMPLEX FORMATION; LONG-TERM; NATURAL-HISTORY; MESANGIAL IGA; OXFORD CLASSIFICATION;
D O I
10.1016/j.nephro.2016.05.005
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
IgA nephropathy is the most common form of primary glomerulonephritis worldwide and an important cause of chronic kidney disease and end-stage kidney failure. Its pathophysiology remains in part unsolved but it is recognized as an immune complex disease. Recent years have brought progress in the field through the discovery of several genetic susceptibility loci and the formulation of the multi-hit pathogenesis model. Presentation, clinical course and histology can be extremely variable, making any histological classification still difficult. Indeed, most therapeutic studies until now include patients based only on the severity of clinical criteria but the new classification of Oxford should change that. Only the management of patients with nephropathy with minimal change glomerular lesions and nephrotic syndrome, or extra-capillary glomerulonephritis and rapidly progressive renal failure, is consensual: Corticosteroids alone for the first and associated with immunosuppressive drugs for the latter. The recent Kidney Disease Improving Global Outcomes (KDIGO) consensus treatment guideline is still controversial, especially in light of the last clinical studies. Corticosteroid therapy can be discussed in patients with proteinuria greater than 1 g/day without renal failure. All IgA nephropathy patients should benefit from the global management of chronic glomerular disease, including a renin-angiotensin system blocker in the presence of hypertension or proteinuria. (C) 2016 Association Societe de nephrologie. Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:238 / 254
页数:17
相关论文
共 50 条
  • [1] ROLE OF IGA IN IGA NEPHROPATHY
    WALDO, FB
    JOURNAL OF PEDIATRICS, 1990, 116 (05): : S78 - S85
  • [2] IgA glycosylation in IgA nephropathy
    Allen, A
    Feehally, J
    GLYCOIMMUNOLOGY 2, 1998, 435 : 175 - 183
  • [3] IgA nephropathy
    Floege, Juergen
    INNERE MEDIZIN, 2023, 64 (10): : 961 - 969
  • [4] IgA nephropathy
    Robles, NR
    MEDICINA CLINICA, 2001, 116 (10): : 373 - 374
  • [5] IGA NEPHROPATHY
    WALLACE, AC
    PATHOLOGY, 1981, 13 (03) : 401 - 403
  • [6] IgA Nephropathy
    Rodrigues, Jennifer C.
    Haas, Mark
    Reich, Heather N.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 12 (04): : 677 - 686
  • [8] IgA nephropathy
    Stamellou, Eleni
    Seikrit, Claudia
    Tang, Sydney C. W.
    Boor, Peter
    Tesar, Vladimir
    Floege, Juergen
    Barratt, Jonathan
    Kramann, Rafael
    NATURE REVIEWS DISEASE PRIMERS, 2023, 9 (01)
  • [9] IgA nephropathy
    Floege, Juergen
    INNERE MEDIZIN, 2023,
  • [10] IgA Nephropathy
    Kazi, Javed Iqbal
    Mubarak, Muhammed
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2010, 20 (12): : 779 - 780